Table 2 Investigational drugs targeting Tie2 pathway
From: The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye
| Â | AXT107 | Faricimab | Razuprotafib | Nesvacumab |
|---|---|---|---|---|
Sponsors | AsclepiX | Roche | Aerpio | Regeneron |
Structure | Peptide | Bispecific antibody | Small molecule | Monoclonal antibody |
Biological effect | Inhibit VEGFR-A/-C Activate Tie2 | Inhibit VEGFR-A and Ang-2 | Activate Tie2 | Inhibit Ang-2 |
Molecular weight (kDa) | 2.357 | 150 | 0.587 | 144.9 |
Route and Dose frequency | IVT every 6-12Â months | IVT every 3-4Â months | Subcutenous twice a day | IVT every 4Â weeks |
Development status | IND filing late 2020 for DME, nAMD and RVO | Phase 3 underway for nAMD and DME | Phase 2 for DME completed | Development terminated |